ANPCY News and Press, Angle Plc Surrey ADR From 02/11/19

New CTC cluster researchpublished in prestigious nature publication f urther demonstrates theimportant role for Parsortix in enabling breakthrough developments in thetreatment of cancer. GUILDFORD, SURREY / ACCESSWIRE / February 11, 2019 / ANGLE plc (AIM: AGL OTCQX: ANPCY),...

Interim Results for the six months ended 31 October 2018 ENROLMENT OF FDA BREAST CANCER STUDY 92% COMPLETE SAMPLE-TO-ANSWER SYSTEM (PARSORTIX-HYCEAD-ZIPLEX) DEVELOPED FOR NEW OVARIAN CANCER STUDY LEVERAGED PARTNERSHIP STRATEGY DIFFERENTIATES BUSINESS GUILDFORD, SUR...

Angle plc ("The Company") Customer Develops New Application for Parsortix System in Cancer Lymph Node Analysis Potential for Parsortix system to improve laboratory efficiency, reduce costs and improve medical decision-making and patient care GUILDFORD, ...